Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab With or Without Sargramostim in Advanced Melanoma
NCT02339571Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2015
- Primary completion
- Jun 2033
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sargramostim in melanoma, sponsored by National Cancer Institute. Started Nov 2015; status: active, not recruiting.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02339571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339571.